Effect of testosterone treatment on the trabecular bone score in older men with low serum testosterone.

Effect of testosterone treatment on the trabecular bone score in older men with low serum testosterone.
复制标题

DOI:
10.1007/s00198-021-06022-1
复制
发表时间:
2021-11
期刊:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
影响因子:
--
通讯作者:
Snyder PJ
Snyder PJ
中科院分区:
其他
文献类型:
--
作者:
Cauley JA;Ellenberg SS;Schwartz AV;Ensrud KE;Keaveny TM;Snyder PJ

文献摘要

参考文献

被引文献

相似文献

在睾酮试验的骨试验中,睾酮治疗增加了小梁体积骨矿物质密度(vBMD),并增加了有限元分析确定的估计骨强度。骨小梁评分(TBS)是椎体骨微结构的间接测量。TBS预测骨折与腰椎区域无关(a)BMD。本研究的目的是检查睾酮治疗对TBS的影响,并与其对vBMD和aBMD的影响进行比较。211名男性入组了Tehran试验的骨试验。其中,197名男性进行了2次重复TBS和vBMD测量; 105名男性被分配接受睾酮治疗,92名男性接受安慰剂治疗,为期一年。在基线和第12个月评估TBS、aBMD和vBMD。随机分组的TBS百分比变化无差异:睾酮组为1.6%(95%置信区间(CI)0.2-3.9),安慰剂组为1.4%(95% CI-0.2,3.1)。相比之下,睾酮组vBMD增加6%(95% CI 4.5-7.5),而安慰剂组为0.4%(95% CI −1.65-0.88)。TBS在监测睾酮治疗对老年性腺功能减退男性骨结构的一年影响方面没有临床意义。骨小梁评分(TBS)是椎体骨微结构的间接测量。我们的目的是检查睾酮治疗对TBS的影响。197名性腺功能减退的男性被随机分配到睾酮组或安慰剂组。12个月后,随机分组的TBS变化无差异。
In the Bone Trial of the Testosterone Trials, testosterone treatment increased trabecular volumetric bone mineral density (vBMD) and increased estimated bone strength as determined by finite element analysis. The Trabecular Bone score (TBS) is an indirect measure of vertebral bone microarchitecture. TBS predicts fracture independent of lumbar spine areal (a)BMD. The objective of this study was to examine the effect of testosterone treatment on TBS compared to its effects on vBMD and aBMD. 211 men were enrolled in the Bone Trial of the Testosterone Trials. Of these, 197 men had 2 repeat TBS and vBMD measurements; 105 men were allocated to receive testosterone and 92 men to placebo for one year. TBS, aBMD and vBMD were assessed at baseline and month 12. There was no difference in the percent change in TBS by randomized group: 1.6% (95% Confidence intervals (CI) 0.2–3.9) in the testosterone group and 1.4% (95% CI −0.2, 3.1) in the placebo group. In contrast, vBMD increased by 6% (95% CI 4.5–7.5) in the testosterone group compared to 0.4% (95% CI −1.65–0.88) in the placebo groups. TBS is not clinically useful in monitoring the one-year effect of testosterone treatment on bone structure in older hypogonadal men. The Trabecular Bone score (TBS) is an indirect measure of vertebral bone microarchitecture. Our objective was to examine the effect of testosterone treatment on TBS. 197 hypogonadal men were randomized to testosterone or placebo. After 12 months, there was no difference in the changes in TBS by randomized group.
DOI: 10.1007/s00198-017-4304-9
发表时间: 2018-03
期刊: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
影响因子: --
作者:
Bilezikian JP;Hattersley G;Fitzpatrick LA;Harris AG;Shevroja E;Banks K;Leder BZ;Zanchetta JR;Hans D
通讯作者: Hans D
DOI: 10.1002/jbmr.1775
发表时间: 2013-03-01
影响因子: 6.2
作者:
Popp, Albrecht W.;Guler, Sabina;Lippuner, Kurt
通讯作者: Lippuner, Kurt
DOI: 10.1016/j.bone.2014.12.062
发表时间: 2015-06-01
期刊: BONE
影响因子: 4.1
作者:
Di Gregorio, S.;Del Rio, L.;Winzenrieth, R.
通讯作者: Winzenrieth, R.
DOI: 10.1016/j.bone.2007.11.018
发表时间: 2008-04-01
期刊: BONE
影响因子: 4.1
作者:
Pothuaud, Laurent;Carceller, Pascal;Hans, Didier
通讯作者: Hans, Didier
DOI: 10.1016/s0026-0495(97)90057-3
发表时间: 1997-04-01
影响因子: 9.8
作者:
Morley, JE;Kaiser, FE;Garry, PJ
通讯作者: Garry, PJ